YHYun-Sheng Hu

Yun-Sheng Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yun-Sheng Hu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Bao-An Ma

    Center of Orthopaedic Surgery, Orthopaedic Oncology Institute of PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, China

    1 shared publication
  • Baoan Ma

    Department of Orthopedic Surgery, Orthopedic Oncology Institute, Tangdu Hospital, Fourth Military Medical University, Xi’an, China

    1 shared publication
  • Degang Fan

    Department of Orthopedic Surgery, Orthopedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, 710038, P. R. China

    1 shared publication
  • Hua Long

    Tangdu Hospital, Fourth Military Medical University, 569 Xinsi Road, Baqiao District, Xi'an, Shaanxi China

    1 shared publication
  • Jun Li

    Department of Joint Surgery Xi'an Honghui Hospital, Xi'an Jiaotong University Xi'an China

    1 shared publication
  • Qingyu Fan

    Department of Orthopedics, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China

    1 shared publication

Latest Publications

  • Open Access

    Expression of MDR1, HIF-1α and MRP1 in sacral chordoma and chordoma cell line CM-319

    by Zhengang Ji, Hua Long, Yunsheng Hu, Xiuchun Qiu, Xiang Chen, Zhao Li, Degang Fan, Baoan Ma, Qingyu Fan

    Background: Chordoma was a typically slow-growing tumor. The therapeutic approach to chordoma had traditionally relied mainly on surgical therapy. And the main reason for therapeutic failure was resistance to chemotherapy and radiotherapy. However the refractory mechanism was not clear. The aim of this study was to investigate the expression of three genes (MDR1,HIF-1αandMRP1) associated with resistance to chemotherapy and radiotherapy in chordoma and chordoma cell line CM-319.Materials and methods: Using immunohistochemical techniques, the expression of MDR1, HIF-1α and MRP1 was investigated in 50 chordoma specimen. Using RT-PCR and Western blot, the expression of MDR1, HIF-1α and MRP1 was investigated in chordoma and chordoma cell line CM-319.Results: Expression of MDR1, HIF-1α and MRP1 was observed in 10%, 80% and 74% of all cases, respectively. Expression of MRP1 was correlated with HIF-1α. On the other hand, expression of MDR1 was not correlated with the expression of HIF-1α or MRP1. The expression of HIF-1α and MRP1 was observed, but MDR1 was not observed in chordoma and CM-319.Conclusion: Expression of HIF-1α and MRP1 was observed in most chordoma specimen and CM-319 cell line; expression of HIF-1α correlated with MRP1. HIF-1α and MRP1 may play a role in the multidrug resistance of chordoma to chemotherapy.


  • Open Access

    Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study

    by Yun-Sheng Hu, Yong Pan, Wen-Hai Li, Yong Zhang, Jun Li, Bao-An Ma

    Background: TGFBR1*6A is a common hypomorphic variant of transforming growth factor β receptor 1 (TGFBR1). TGFBR1*6A is associated with an increased cancer risk, but the association of this polymorphism with osteosarcoma remains unknown. We have measured the frequency of TGFBR1*6A variants in osteosarcoma cases and controls. Methods: Our case-control study is based on 168 osteosarcoma patients and 168 age- and gender-matched controls. Blood samples were obtained and the TGFBR1*6A variant determined by PCR amplification and DNA sequencing. The odds ratio (OR) and 95% confidence interval (95% CI) for the TGFBR1*6A polymorphism were calculated by unconditional logistic regression, adjusted for both age and gender. Three models - dominant, additive and recessive - were used to analyze the contribution of the TGFBR1*6A variant to osteosarcoma susceptibility. Results: Heterozygotic and homozygotic TGFBR1*6A variants represented 50.4% and 6.0% of the 168 cases, whereas the controls had 18. 5% and 1.3%, respectively. ORs for homozygosity and heterozygosity of the TGFBR1*6A allele were 4.6 [95% CI, 2.33-7.97] and 2.9 [95% CI, 1.59-5.34] in the additive model. There were significant increases in the TGFBR1*6A variants in osteosarcoma cases compared to control in all 3 models. Further analysis showed that TGFBR1*6A genotypes were not associated with gender, age, or tumor location. However, TGFBR1*6A was significantly associated with less metastasis. Conclusions: TGFBR1*6A, a dominant polymorphism of TGFBR1, is associated with increased susceptibility and metastasis spread of osteosarcoma.